Toni K Choueiri Selected Research

Vascular Endothelial Growth Factor Receptors (VEGF Receptors)

10/2022	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
1/2022	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial.
1/2021	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma.
1/2021	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).
11/2018	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
10/2018	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
1/2018	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
11/2015	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
10/2015	Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.
8/2015	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toni K Choueiri Research Topics

Disease

294	Renal Cell Carcinoma (Grawitz Tumor) 10/2022 - 12/2003
236	Neoplasms (Cancer) 11/2022 - 08/2004
67	Prostatic Neoplasms (Prostate Cancer) 03/2022 - 03/2006
43	Carcinoma (Carcinomatosis) 03/2022 - 03/2006
37	Neoplasm Metastasis (Metastasis) 01/2022 - 03/2006
31	Kidney Neoplasms (Kidney Cancer) 01/2022 - 08/2007
25	Fatigue 10/2021 - 06/2008
22	Disease Progression 01/2022 - 12/2010
18	Hypertension (High Blood Pressure) 01/2022 - 06/2008
15	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 08/2008
12	Hypoxia (Hypoxemia) 01/2022 - 10/2006
9	Melanoma (Melanoma, Malignant) 01/2022 - 12/2014
7	Breast Neoplasms (Breast Cancer) 05/2014 - 08/2004
6	Adenocarcinoma 03/2022 - 06/2012
6	COVID-19 01/2022 - 01/2020
6	Nausea 01/2021 - 05/2010
6	Exanthema (Rash) 01/2021 - 08/2004
6	Diarrhea 01/2021 - 06/2008
6	Anemia 01/2018 - 11/2011
5	Hematologic Neoplasms (Hematological Malignancy) 03/2022 - 12/2003
5	Brain Neoplasms (Brain Tumor) 12/2021 - 09/2006
5	Heart Failure 09/2015 - 02/2011
4	Margins of Excision 10/2019 - 11/2011
4	Hypothyroidism 01/2018 - 01/2017
4	Pneumonia (Pneumonitis) 01/2017 - 07/2012
4	Hand-Foot Syndrome 05/2016 - 06/2008
4	Transitional Cell Carcinoma 07/2012 - 04/2010
3	Infections 11/2021 - 09/2005
3	Carcinogenesis 01/2021 - 11/2012
3	Obesity 01/2020 - 12/2012

Drug/Important Bio-Agent (IBA)

67	Sunitinib (Sutent)FDA Link 10/2022 - 01/2008
55	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2021 - 10/2006
49	Immune Checkpoint InhibitorsIBA 10/2022 - 11/2015
45	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2013
32	AndrogensIBA 01/2022 - 03/2009
31	NivolumabIBA 07/2022 - 06/2015
28	Everolimus FDA Link 01/2022 - 05/2011
27	cabozantinibIBA 07/2022 - 11/2015
24	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2008
17	Axitinib (AG 013736)IBA 10/2022 - 06/2008
17	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2022 - 10/2009
17	Pharmaceutical PreparationsIBA 01/2022 - 11/2011
16	PlatinumIBA 03/2022 - 04/2010
16	pazopanib FDA Link 01/2021 - 03/2011
16	Prostate-Specific Antigen (Semenogelase)IBA 01/2020 - 03/2009
14	pembrolizumabIBA 01/2022 - 01/2016
14	IpilimumabIBA 01/2022 - 01/2017
14	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 11/2012
14	Bevacizumab (Avastin)FDA Link 01/2021 - 05/2009
14	Proteins (Proteins, Gene)FDA Link 11/2020 - 03/2006
14	Sorafenib (BAY 43-9006)FDA Link 01/2019 - 01/2008
11	RNA (Ribonucleic Acid)IBA 01/2022 - 07/2014
11	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 05/2007
11	Hemoglobins (Hemoglobin)IBA 01/2018 - 03/2008
10	MTOR InhibitorsIBA 01/2022 - 08/2010
10	B7-H1 AntigenIBA 01/2022 - 07/2014
10	atezolizumabIBA 01/2022 - 01/2018
10	LigandsIBA 11/2020 - 01/2014
9	Biological ProductsIBA 01/2022 - 06/2015
9	TOR Serine-Threonine KinasesIBA 08/2016 - 06/2009
8	avelumabIBA 10/2022 - 01/2018
8	Angiogenesis InhibitorsIBA 05/2014 - 10/2006
7	Messenger RNA (mRNA)IBA 10/2021 - 08/2014
7	Phosphotransferases (Kinase)IBA 10/2018 - 06/2008
6	Monoclonal AntibodiesIBA 01/2021 - 11/2015
6	Formaldehyde (Formol)FDA Link 12/2018 - 07/2014
6	ParaffinIBA 12/2018 - 11/2013
5	Cell-Free Nucleic AcidsIBA 03/2022 - 01/2020
5	Lipase (Acid Lipase)FDA Link 01/2021 - 08/2016
5	temsirolimus FDA Link 01/2020 - 05/2009
5	Docetaxel (Taxotere)FDA Link 01/2018 - 07/2011
5	Hormones (Hormone)IBA 01/2015 - 08/2004
4	lenvatinibIBA 01/2022 - 03/2019
4	Transcription Factors (Transcription Factor)IBA 01/2021 - 10/2009
4	Alanine Transaminase (SGPT)IBA 10/2019 - 08/2013
4	vinflunineIBA 01/2017 - 04/2010
3	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2018
3	abirateroneIBA 01/2022 - 10/2017
3	enzalutamideIBA 01/2022 - 10/2017
3	Circulating Tumor DNAIBA 12/2021 - 10/2017
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 01/2017
3	Amylases FDA Link 10/2019 - 08/2016

Therapy/Procedure

256	Therapeutics 10/2022 - 08/2004
36	Drug Therapy (Chemotherapy) 03/2022 - 03/2006
35	Immunotherapy 11/2022 - 11/2007
27	Nephrectomy 01/2022 - 12/2008
20	Prostatectomy (Retropubic Prostatectomy) 10/2019 - 11/2008
15	Radiotherapy 03/2021 - 08/2008
10	Cystectomy 12/2021 - 08/2008
9	Brachytherapy 01/2019 - 10/2010
7	Castration 03/2022 - 10/2009
7	Neoadjuvant Therapy 12/2021 - 10/2012
6	Metastasectomy 01/2021 - 02/2011
5	Aftercare (After-Treatment) 01/2022 - 02/2011
4	Time-to-Treatment 01/2020 - 08/2010
4	Adjuvant Chemotherapy 02/2018 - 07/2014
4	Salvage Therapy 01/2018 - 04/2010
4	Lymph Node Excision (Lymph Node Dissection) 01/2018 - 05/2007
3	Orchiectomy (Orchidectomy) 11/2021 - 12/2014
3	Duration of Therapy 01/2020 - 09/2012